Piper Sandler Raises Price Target for Abivax (ABVX)

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 12 Best Performing Stocks in the Last 6 Months. On July 29, Piper Sandler increased its price target for ABIVAX Société Anonyme (NASDAQ:ABVX) from $70 to $112 while keeping an “Overweight” rating.

This decision came after the research firm’s analysis of ABIVAX’s Société Anonyme (NASDAQ:ABVX) Phase 3 induction data for Obefazimod in Ulcerative Colitis (UC). Piper Sandler incorporated into its financial models the revenue potential in early-line UC treatment. This effectively doubled the firm’s revenue forecast in UC for the US market to EUR 2.656 billion by 2035.

Additionally, Piper Sandler identified a number of upcoming catalysts for ABIVAX’s Société Anonyme (NASDAQ:ABVX). These include the possibility of full presentation of UC induction data at a medical meeting in October, the release of Phase 3 UC maintenance data expected in the second quarter of 2026, and Phase 2b data for Crohn’s disease expected in the second half of 2026.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a French clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.